Considering that immunometabolism has emerged as a central element in cancer therapy (52, 53), we previously explored the combination of gDE7 with IDO inhibitors and melatonin, which promoted synergic antitumor effects drawing attention to the relevance of multi-target therapeutic approaches (27). Here, GDPD3 is linked to cancer.